Alossaimi Manal A, Aldakhil Taibah, Elmansi Heba, Belal Fathalla, Magdy Galal
Pharmaceutical Chemistry Department, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Pharmaceutical Chemistry Department, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Biophys Chem. 2025 Dec;327:107512. doi: 10.1016/j.bpc.2025.107512. Epub 2025 Aug 12.
The study of the interaction between small molecules and biological macromolecules is a critical area of research with significant implications across various scientific fields. Larotrectinib, a tropomyosin kinase inhibitor, is used to treat patients with solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. In this investigation, the interaction between larotrectinib and calf thymus DNA (ctDNA) was thoroughly examined using a combination of techniques, including UV-Vis spectrophotometry, spectrofluorimetry, viscosity measurements, ionic strength variation, thermodynamic analysis, molecular dynamics simulations, and docking studies. The results demonstrated a strong binding interaction between larotrectinib and ctDNA, with the drug primarily binding to the minor groove of ctDNA. This binding mode was established through competitive binding assays using ethidium bromide and rhodamine B, as well as UV-Vis spectroscopy and viscosity analysis. The binding constant (K) at 298 K, determined using the Benesi-Hildebrand equation, was found to be 4.4 × 10 M, pointing out a high binding affinity between larotrectinib and ctDNA. Thermodynamic analysis revealed that the interaction is driven mainly by hydrophobic forces and hydrogen bonding, as evidenced by the calculated enthalpy (ΔH) and entropy (ΔS) changes. Molecular docking studies further supported these findings, showing that larotrectinib binds preferentially to the AT-rich regions of the B-DNA minor groove. This was validated by molecular dynamics studies, which provided additional confirmation of the binding mechanism. Overall, these findings provide valuable understanding into the molecular interactions and pharmacological mechanisms of larotrectinib, contributing to a deeper insight of its role as a potent anticancer agent.
小分子与生物大分子之间相互作用的研究是一个关键的研究领域,在各个科学领域都具有重要意义。拉罗替尼是一种原肌球蛋白激酶抑制剂,用于治疗患有神经营养性酪氨酸受体激酶(NTRK)基因融合的实体瘤患者。在本研究中,使用紫外-可见分光光度法、荧光分光光度法、粘度测量、离子强度变化、热力学分析、分子动力学模拟和对接研究等多种技术,对拉罗替尼与小牛胸腺DNA(ctDNA)之间的相互作用进行了深入研究。结果表明,拉罗替尼与ctDNA之间存在强烈的结合相互作用,药物主要与ctDNA的小沟结合。这种结合模式是通过使用溴化乙锭和罗丹明B的竞争性结合试验以及紫外-可见光谱和粘度分析确定的。使用贝内西-希尔德布兰德方程测定的298K时的结合常数(K)为4.4×10 M,表明拉罗替尼与ctDNA之间具有高结合亲和力。热力学分析表明,这种相互作用主要由疏水力和氢键驱动,计算得到的焓变(ΔH)和熵变(ΔS)证明了这一点。分子对接研究进一步支持了这些发现,表明拉罗替尼优先结合到B-DNA小沟富含AT的区域。分子动力学研究验证了这一点,进一步证实了结合机制。总体而言,这些发现为拉罗替尼的分子相互作用和药理机制提供了有价值的理解,有助于更深入地了解其作为一种强效抗癌药物的作用。